Parathyroid cancer differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 10: | Line 10: | ||
* [[Malignancy]] (esp. [[squamous cell carcinoma]], [[plasmacytoma]]) | * [[Malignancy]] (esp. [[squamous cell carcinoma]], [[plasmacytoma]]) | ||
* Endocrine ([[primary hyperparathyroidism]], [[tertiary hyperparathyroidism]], familial hypocalciuric hypercalcemia (FHH)) | * Endocrine ([[primary hyperparathyroidism]], [[tertiary hyperparathyroidism]], familial hypocalciuric hypercalcemia (FHH)) | ||
* | * Drug adverse effects such as [[thiazides]] | ||
==Reference== | ==Reference== |
Revision as of 20:10, 29 December 2015
Parathyroid cancer Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Parathyroid cancer differential diagnosis On the Web |
American Roentgen Ray Society Images of Parathyroid cancer differential diagnosis |
Risk calculators and risk factors for Parathyroid cancer differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Parathyroid cancer must be differentiated from renal disease, immobility, and granulomatous diseases.[1]
Differentiating Parathyroid cancer from other Diseases
- Granulomatous disease (tuberculosis, sarcoidosis)
- Renal disease
- Immobility
- Malignancy (esp. squamous cell carcinoma, plasmacytoma)
- Endocrine (primary hyperparathyroidism, tertiary hyperparathyroidism, familial hypocalciuric hypercalcemia (FHH))
- Drug adverse effects such as thiazides
Reference
- ↑ Parathyroid cancer. Canadian Cancer Society (2015). http://www.cancer.ca/en/cancer-information/cancer-type/parathyroid/parathyroid-cancer/?region=bc Accessed on December 29, 2015